AC6 Stock Chart & Stats
€0.15
>-€0.01(-7.07%)
At close: 4:00 PM EST
€0.15
>-€0.01(-7.07%)
Day’s Range― - ―
52-Week Range€0.07 - €0.74
Previous CloseN/A
Volume0.00
Average Volume (3M)114.00
Market Cap
€76.45M
Enterprise Value€162.38
Total Cash (Recent Filing)€32.97M
Total Debt (Recent Filing)€2.29M
Price to Earnings (P/E)―
Beta-0.30
Next Earnings
Aug 26, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.53
Shares Outstanding137,897,340
10 Day Avg. Volume0
30 Day Avg. Volume114
Financial Highlights & Ratios
PEG Ratio-1.96
Price to Book (P/B)6.11
Price to Sales (P/S)0.00
P/FCF Ratio-5.81
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.03
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Focused CNS R&D PipelineAlzeCure’s strategy concentrates on proprietary R&D for CNS indications (Alzheimer’s and pain), creating a clear, durable business focus. For a development-stage biotech, concentrated scientific efforts and platform specialization can drive efficient resource allocation and long-term value if clinical milestones are met.
Low Leverage On Balance SheetThe company’s low debt-to-equity ratio reduces refinancing and interest-rate pressure, providing structural financial flexibility. Lower leverage means less fixed financing cost during development cycles, helping the firm preserve cash for R&D and withstand multi-stage clinical timelines relative to heavily indebted peers.
Lean Operating StructureA very small headcount indicates a lean cost base and operational flexibility. For a pre-revenue biotech, low fixed overhead supports longer runway per financing round, easier scaling via external partnerships or CROs, and more targeted allocation of capital toward critical clinical and discovery activities.
Bears Say
No Revenue; Large Persistent LossesThe absence of commercial revenue combined with sizable recurring losses means the business cannot self-fund development. Persistent negative profitability steadily consumes capital, reducing optionality and increasing dependency on external financing or partnerships to progress clinical programs over the medium term.
Heavy Negative Cash FlowDeeply negative operating and free cash flow is a structural constraint: it requires frequent external funding to maintain operations and advance trials. Over time this raises dilution risk, diverts management focus to financing, and limits ability to invest steadily in multiple development programs without new capital.
Rapid Equity Erosion And Financing RiskThe sharp decline in equity indicates sustained capital consumption and likely recurring financing activity. A shrinking equity base increases probability of future dilution, constrains strategic options, and signals that long-term viability depends on successful funding rounds or milestone events rather than internal cash generation.
AC6 FAQ
What was AlzeCure Pharma AB’s price range in the past 12 months?
AlzeCure Pharma AB lowest stock price was €0.07 and its highest was €0.74 in the past 12 months.
What is AlzeCure Pharma AB’s market cap?
AlzeCure Pharma AB’s market cap is €76.45M.
When is AlzeCure Pharma AB’s upcoming earnings report date?
AlzeCure Pharma AB’s upcoming earnings report date is Aug 26, 2026 which is in 21 days.
How were AlzeCure Pharma AB’s earnings last quarter?
AlzeCure Pharma AB released its earnings results on May 05, 2026. The company reported -€0.015 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.015.
Is AlzeCure Pharma AB overvalued?
According to Wall Street analysts AlzeCure Pharma AB’s price is currently Overvalued.
Does AlzeCure Pharma AB pay dividends?
AlzeCure Pharma AB does not currently pay dividends.
What is AlzeCure Pharma AB’s EPS estimate?
AlzeCure Pharma AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does AlzeCure Pharma AB have?
AlzeCure Pharma AB has 137,897,340 shares outstanding.
What happened to AlzeCure Pharma AB’s price movement after its last earnings report?
AlzeCure Pharma AB reported an EPS of -€0.015 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -6.024%.
Which hedge fund is a major shareholder of AlzeCure Pharma AB?
Currently, no hedge funds are holding shares in DE:AC6
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
AlzeCure Pharma AB
AlzeCure Pharma AB (publ) operates as a pharmaceutical company that develops drug therapies for the treatment of severe diseases and conditions that affect the central nervous system. The company is involved in the development of drug candidates based on the NeuroRestore, Alzstatin, and Painless research platforms. Its products pipeline includes ACD856 for the treatment of Alzheimer’s disease, sleep disorders, depression, traumatic brain injuries, and Parkinson’s disease, which is in phase I clinical trial; ACD857, ACD679, and ACD680 that are in preclinical trial for the treatment of Alzheimer’s disease; ACD440, a TRPV1 antagonist that has completed phase I clinical trial for neuropathic pain indications; and ACD137, negative allosteric modulator (NAM) of TrkA receptors for osteoarthritic pain indications. The company was founded in 2012 and is based in Huddinge, Sweden.